Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-42160443 adjunctive therapy for cancer-related pain
2008-007690-21Phase 2Terminated
- Sponsor
- Johnson & Johnson
- Start
- Mar 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of fulranumab in cancer pain (3 arms), sponsored by Johnson & Johnson. Primary endpoint: Average cancer-related pain intensity in the last 24 hours. Started Mar 2009; status: terminated.
02
Drugs
fulranumab
03
Conditions
cancer pain
Beyond the preview
Go deeper on 2008-007690-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007690-21.